Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

26.24 +0.97 (+3.84%)
Streaming Delayed Price Updated: 11:13 AM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
Via ACCESS Newswire
News headline image
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
NASDAQ:AMPH is an undervalued gem with solid fundamentals. ↗
AMPHASTAR PHARMACEUTICALS IN is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:AMPH showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
Via ACCESSWIRE
News headline image
Why the growth investor may take a look at NASDAQ:AMPH. ↗
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
Exploring NASDAQ:AMPH's growth characteristics. ↗
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations 
Via Chartmill
News headline image
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Investors should take notice of NASDAQ:AMPH—it offers a great deal for the fundamentals it presents. ↗
AMPHASTAR PHARMACEUTICALS IN has caught the attention as a great value stock. NASDAQ:AMPH excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
News headline image
NASDAQ:AMPH is an undervalued gem with solid fundamentals. ↗
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Via ACCESSWIRE
News headline image
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade ↗
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
News headline image
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
News headline image
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
Via ACCESSWIRE
News headline image
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024 ↗
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
Via ACCESSWIRE
News headline image
7 Biotech Stocks to Buy on the Dip: June 2024 ↗
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
News headline image
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each 
Via MarketBeat
Topics ETFs Economy
News headline image
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Via ACCESSWIRE
News headline image
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
Via ACCESSWIRE
News headline image
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
News headline image
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
Via ACCESSWIRE
News headline image
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024 ↗
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.